New approach in prophylactic treatment of a challenged HAE patient

Oda Jordal*, Anette Bygum

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

117 Downloads (Pure)

Abstract

Hereditary angioedema (HAE) is a relapsing swelling disorder which can cause severe pain, affect quality of life and potentially be life threatening with involvement of the airways. We present a 34-year-old immigrant who suffered from very frequent and severe HAE attacks. The attacks often involved the face, mouth and the airways. She often went to the hospital for treatment, where the language barrier made the situation complicated. The traditional therapy for HAE was not successful treating this patient. In June 2017, off-label treatment with prophylactic subcutaneous complement C1-inhibitor concentrate was initiated. The treatment was very successful and the patient has not been hospitalised since. Treatment for HAE is nowadays under investigation, and many drugs are under development. Especially, medication which works prophylactically and is administered orally or subcutaneously is in the horizon.

Original languageEnglish
Article numbere227061
JournalBMJ Case Reports
Volume12
Issue number3
Number of pages4
ISSN1757-790X
DOIs
Publication statusPublished - 4. Mar 2019

Bibliographical note

This article has been accepted for publication in BMJ Case Reports, 2019 following peer review, and the Version of Record can be accessed online at http://dx.doi.org/10.1136/bcr-2018-227061.
© Authors. Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (CC-BY-NC 4.0) http://creativecommons.org. https://creativecommons.org/licenses/by-nc/4.0.

Keywords

  • Adult
  • Angioedemas, Hereditary/drug therapy
  • Complement C1 Inhibitor Protein/pharmacology
  • Complement Inactivating Agents/pharmacology
  • Female
  • Humans
  • Off-Label Use
  • Patient Education as Topic
  • Quality of Life
  • Self Administration
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'New approach in prophylactic treatment of a challenged HAE patient'. Together they form a unique fingerprint.

Cite this